NASDAQ:NTECIntec Pharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Intec Pharma Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.37 -0.04 (-8.71 %) (As of 08/12/2020 04:00 PM ET) Add Compare Share Today's Range$0.37Now: $0.37▼$0.4150-Day Range$0.27MA: $0.36▼$0.5352-Week Range$0.13Now: $0.37▼$1.56Volume4.44 million shsAverage Volume6.35 million shsMarket Capitalization$26.49 millionP/E RatioN/ADividend YieldN/ABeta0.94 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various indications, including low back pain, neuropathic pain, and fibromyalgia. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.Read More Beat the Market (BTM) Rank™ 3.0 Analyst's Opinion Consensus RatingIntec Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.00, Intec Pharma has a potential upside of 171.1% from its current price of $0.37.Amount of Analyst CoverageIntec Pharma has only been the subject of 2 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesIntec Pharma has received 279 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIntec Pharma has received 313 “underperform” votes. (Add your “underperform” vote.)Community SentimentIntec Pharma has received 52.87% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Intec Pharma and other stocks. Vote “Outperform” if you believe NTEC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NTEC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIntec Pharma does not currently pay a dividend.Dividend GrowthIntec Pharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intec Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of Intec Pharma is held by insiders.Percentage Held by InstitutionsOnly 11.15% of the stock of Intec Pharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Intec Pharma are expected to grow in the coming year, from ($0.23) to ($0.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intec Pharma is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intec Pharma is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntec Pharma has a P/B Ratio of 1.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.21 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NTEC Previous Symbol CUSIPN/A CIK1638381 Webwww.intecpharma.com Phone972-2586-4657Debt Debt-to-Equity RatioN/A Current Ratio3.45 Quick Ratio3.45Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book1.68Profitability EPS (Most Recent Fiscal Year)($1.09) Net Income$-47,600,000.00 Net MarginsN/A Return on Equity-140.77% Return on Assets-88.54%Miscellaneous Employees38 Outstanding Shares71,839,000Market Cap$26.49 million Next Earnings Date11/10/2020 (Estimated) OptionableOptionable $0.37 -0.04 (-8.71 %) (As of 08/12/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive NTEC News and Ratings via Email Sign-up to receive the latest news and ratings for NTEC and its competitors with MarketBeat's FREE daily newsletter. Intec Pharma (NASDAQ:NTEC) Frequently Asked Questions How has Intec Pharma's stock price been impacted by COVID-19? Intec Pharma's stock was trading at $0.2388 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NTEC stock has increased by 54.4% and is now trading at $0.3688. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Intec Pharma? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intec Pharma in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Intec Pharma. When is Intec Pharma's next earnings date? Intec Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Intec Pharma. How were Intec Pharma's earnings last quarter? Intec Pharma Ltd (NASDAQ:NTEC) posted its quarterly earnings results on Wednesday, August, 5th. The biotechnology company reported ($0.05) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.05) by $0.00. View Intec Pharma's earnings history. What price target have analysts set for NTEC? 4 equities research analysts have issued 1-year price targets for Intec Pharma's shares. Their forecasts range from $1.00 to $1.00. On average, they anticipate Intec Pharma's share price to reach $1.00 in the next year. This suggests a possible upside of 171.1% from the stock's current price. View analysts' price targets for Intec Pharma. Has Intec Pharma been receiving favorable news coverage? News stories about NTEC stock have been trending somewhat negative recently, InfoTrie reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Intec Pharma earned a coverage optimism score of -1.2 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Intec Pharma. Are investors shorting Intec Pharma? Intec Pharma saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 279,900 shares, an increase of 777.4% from the April 30th total of 31,900 shares. Based on an average daily volume of 5,610,000 shares, the days-to-cover ratio is presently 0.0 days. View Intec Pharma's Short Interest. Who are some of Intec Pharma's key competitors? Some companies that are related to Intec Pharma include Iterum Therapeutics (NRBO), Otonomy (OTIC), Zosano Pharma (ZSAN), Aptorum Group (APM), Qualigen (QLGN), Savara (SVRA), Endonovo Therapeutics (ENDV), Leap Therapeutics (LPTX), Zynerba Pharmaceuticals (ZYNE), Antibe Therapeutics (ATBPF), Trevi Therapeutics (TRVI), Lipocine (LPCN), Eyenovia (EYEN), OncoSec Medical (ONCS) and Galmed Pharmaceuticals (GLMD). View all competitors. What other stocks do shareholders of Intec Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intec Pharma investors own include SCYNEXIS (SCYX), Canopy Growth (CGC), Onconova Therapeutics (ONTX), Actinium Pharmaceuticals (ATNM), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), Viking Therapeutics (VKTX), Corbus Pharmaceuticals (CRBP) and Aurora Cannabis (ACB). Who are Intec Pharma's key executives? Intec Pharma's management team includes the following people: Mr. Jeffrey A. Meckler, Vice Chairman & CEO (Age 53, Pay $786.9k)Mr. Nir Sassi, Chief Financial Officer (Age 44, Pay $338.11k)Dr. Nadav Navon Ph.D., Chief Operating Officer (Age 51, Pay $394.94k)Mr. Walt Addison Linscott, Chief Bus. Officer (Age 59, Pay $557.05k)Dr. R. Michael Gendreau, Chief Medical Officer (Age 64, Pay $459.15k) When did Intec Pharma IPO? (NTEC) raised $30 million in an initial public offering on Tuesday, August 4th 2015. The company issued 5,000,000 shares at a price of $6.00 per share. Maxim Group and Roth Capital Partners served as the underwriters for the IPO. What is Intec Pharma's stock symbol? Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC." Who are Intec Pharma's major shareholders? Intec Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Integrated Wealth Concepts LLC (0.60%), Harel Insurance Investments & Financial Services Ltd. (0.53%) and Russell Investments Group Ltd. (0.15%). Company insiders that own Intec Pharma stock include Anthony J Maddaluna, Issac Silberman, Jeffrey A Meckler and Pharma Technologies Ltd Dexcel. View institutional ownership trends for Intec Pharma. Which institutional investors are buying Intec Pharma stock? NTEC stock was purchased by a variety of institutional investors in the last quarter, including Integrated Wealth Concepts LLC, Harel Insurance Investments & Financial Services Ltd., and Russell Investments Group Ltd.. Company insiders that have bought Intec Pharma stock in the last two years include Anthony J Maddaluna, and Jeffrey A Meckler. View insider buying and selling activity for Intec Pharma. How do I buy shares of Intec Pharma? Shares of NTEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Intec Pharma's stock price today? One share of NTEC stock can currently be purchased for approximately $0.37. How big of a company is Intec Pharma? Intec Pharma has a market capitalization of $26.49 million. The biotechnology company earns $-47,600,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. Intec Pharma employs 38 workers across the globe. What is Intec Pharma's official website? The official website for Intec Pharma is www.intecpharma.com. How can I contact Intec Pharma? Intec Pharma's mailing address is 12 HARTOM STREET HAR HOTZVIM, JERUSALEM L3, 777512. The biotechnology company can be reached via phone at 972-2586-4657 or via email at [email protected] This page was last updated on 8/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
